drugset / Trial / NCT01857232

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

NCT01857232

Phase 2 Completed 342 enrolled Acacia Pharma Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy

Timeline

Start
2013-10
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 10 mg Intravenous
Subject Amisulpride Small molecule 20 mg Intravenous
Subject Amisulpride Small molecule 40 mg Intravenous
Background Dexamethasone Small molecule
Background Fosaprepitant Other / unclassified
Background Ondansetron Other / unclassified 8 mg Intravenous
Background Ondansetron Other / unclassified 16 mg Intravenous

Indications

No indication recorded.